Author:
Cook Elise D.,Nelson Ana C.
Publisher
Springer Science and Business Media LLC
Reference26 articles.
1. •• Hugosson J, Carlsson S, Aus G, et al.: Mortality results from the Goteborg randomized population-based prostate-cancer screening trial. Lancet Oncol 2010, 11:725–732. The Goteborg study’s first report on cumulative prostate cancer incidence and mortality demonstrated a significant reduction in prostate cancer mortality over a 14-year period, and the benefit of prostate cancer screening compared favorably to that of other cancer screenings.
2. •• Schroder FH, Hugosson J, Roobol MJ, et al.: Screening and prostate-cancer mortality in a randomized European study. N Eng J Med 2009, 360:1320–1328. Data from the ERSPC trial showed that PSA-based screening decreased the prostate cancer-related mortality rate by 20%.
3. Jemal A, Siegel R, Xu J, Ward E: Cancer Statistics 2010. CA Cancer J Clin 2010, 60:277–300.
4. National Cancer Institute, US National Institutes of Health: Cancer advances in focus: prostate cancer. Available at http://www.cancer.gov/cancertopics/cancer-advances-in-focus/prostate . Accessed July 19, 2010.
5. Catalona WJ, Smith DS, Ratliff TL, et al.: Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Eng J Med 1991, 324:1156–1161.
Cited by
21 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献